Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Portugal: An Uptick In Life Science VC Funding

Executive Summary

An international VC, Vesalius Biocapital, is to invest in start-up life sciences and biotech companies in the western European country that is developing an entrepreneurial ecosystem.

You may also be interested in...



Vesalius’s “Proven Investment Strategy” Reflected In Largest Fund Close To Date

European fund manager Vesalius has closed its third fund with €120m. Its managers believe their strategy of investing in maturing companies has been the key to attracting commitments, including from the European Investment Fund.

Austerity in Portugal drops drug bill 21%, drives parallel exports, hospital debt

Market conditions in Portugal are continuing to deteriorate as cost cutting has fuelled parallel exports and hospitals owe companies increasingly more money, APIFARMA, the local R&D-based pharmaceutical industry association, has warned.

Rare Genetic Epilepsy Responsive To Marinus's Ganaxolone

Marinus Pharmaceuticals has transformed its finances and the prospects for its R&D pipeline over the past 12 months, and has just reported positive top-line results from the Phase III MARIGOLD study of its lead compound, ganaxolone.

Topics

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel